open access
Measurement of HE4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer
, 1, 2, 1, 2, 1
Affiliations- Independent laboratory of Tumor Biomarkers and Cytokines, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
open access
Abstract
Objectives: The objective of the study was to assess the usefulness of determining HE4 and CA125 in ovarian cancer
patients, to indicate which of the measurements may be optimal in the prognosis, depending on the treatment scheme.
Material and methods: The concentrations of CA125 and HE4 were performed in 70 patients with advanced ovarian
cancer during I-line therapy and after treatment. The subjects were divided based on the treatment scheme: group
I - primary surgery and adjuvant chemotherapy, II- neoadjuvant therapy, and surgery.
Results: Multivariate analysis showed that HE4 levels six months after treatment was significantly higher in patients with
disease progression. ROC analysis in the group of patients treated with neoadjuvant therapy showed that the cut-off
values indicating relapse for HE4 and CA125 after six months of follow up, were > 90.4 pmol/L, > 25.6 IU/mL, respectively. In the group of patients not treated with neoadjuvant therapy, the cut-off points differentiating patients with progression were: HE4 > 79.1 pmol/L, CA125 > 30.7 IU/mL. We demonstrated significantly higher HE4 and CA125 at both 6- and 12-months follow-up in patients treated with neoadjuvant therapy. In both groups of patients, the cut-off points were lower than those proposed by the manufacturer of the kits.
Conclusions: Measurement of HE4 six months after treatment may be useful in identifying patients at high risk of
progression, especially when CA125 levels may be non-specifically elevated. The cut-off values indicating relapse for
HE4 and CA125 after six months of follow up may be lower than the normal range.
Abstract
Objectives: The objective of the study was to assess the usefulness of determining HE4 and CA125 in ovarian cancer
patients, to indicate which of the measurements may be optimal in the prognosis, depending on the treatment scheme.
Material and methods: The concentrations of CA125 and HE4 were performed in 70 patients with advanced ovarian
cancer during I-line therapy and after treatment. The subjects were divided based on the treatment scheme: group
I - primary surgery and adjuvant chemotherapy, II- neoadjuvant therapy, and surgery.
Results: Multivariate analysis showed that HE4 levels six months after treatment was significantly higher in patients with
disease progression. ROC analysis in the group of patients treated with neoadjuvant therapy showed that the cut-off
values indicating relapse for HE4 and CA125 after six months of follow up, were > 90.4 pmol/L, > 25.6 IU/mL, respectively. In the group of patients not treated with neoadjuvant therapy, the cut-off points differentiating patients with progression were: HE4 > 79.1 pmol/L, CA125 > 30.7 IU/mL. We demonstrated significantly higher HE4 and CA125 at both 6- and 12-months follow-up in patients treated with neoadjuvant therapy. In both groups of patients, the cut-off points were lower than those proposed by the manufacturer of the kits.
Conclusions: Measurement of HE4 six months after treatment may be useful in identifying patients at high risk of
progression, especially when CA125 levels may be non-specifically elevated. The cut-off values indicating relapse for
HE4 and CA125 after six months of follow up may be lower than the normal range.
Keywords
CA125; human epididymis 4; ovarian cancer; treatment monitoring; progression
About this articleTitle
Measurement of HE4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer
Journal
Issue
Article type
Research paper
Pages
910-915
Published online
2022-10-11
Page views
3721
Article views/downloads
328
DOI
Pubmed
Bibliographic record
Ginekol Pol 2022;93(11):910-915.
Keywords
CA125
human epididymis 4
ovarian cancer
treatment monitoring
progression
Authors
Beata U. Kotowicz
Malgorzata Fuksiewicz
Mariusz Bidzinski
Alicja Berezowska
Piotr Sobiczewski
Maria M. Kowalska
References (23)- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
- Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2017. https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2017-statistics/2017_canadian-cancer-statistics_en.pdf?rev=ee02481cb5594aad8405978fc9e3a3f4&hash=95B537DFF1B937F18EF98BC0CB4BFE02&_ga=2.37148256.1130170704.1649181242-1299171446.1643304033 (26.04.2022).
- SEER Cancer Statistics Review (CSR) 1975-2015. https://seer.cancer.gov/archive/csr/1975_2015/ (26.04.2022).
- Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013; 19(5): 961–968.
- Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019; 111(1): 60–68.
- du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009; 115(6): 1234–1244.
- Penninkilampi R, Eslick GD. Perineal talc use and ovarian cancer: a systematic review and meta-analysis. Epidemiology. 2018; 29(1): 41–49.
- Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21): 2654–2663.
- Zhang X, Devins K, Ko EM, et al. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors. Gynecol Oncol. 2021; 161(3): 762–768.
- Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460(3): 237–249.
- Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012; 226(3): 413–420.
- Chui MH, Kjaer SK, Frederiksen K, et al. BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget. 2019; 10(64): 6870–6878.
- Riester M, Wei W, Waldron L, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014; 106(5): dju048.
- Kotowicz B, Fuksiewicz M, Sobiczewski P, et al. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages. Eur J Obstet Gynecol Reprod Biol. 2015; 194: 141–146.
- Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017; 17(6): 577–591.
- Wang Q, Wu Y, Zhang H, et al. Clinical value of serum HE4, CA125, CA72-4, and ROMA index for diagnosis of ovarian cancer and prediction of postoperative recurrence. Clin Lab. 2019; 65(4).
- Yi G, Ying-xing Z, Ping M. HE4 Levels for Detecting Recurrence in Ovarian Cancer: A Systematic Review and Meta-Analysis. Am J Biomed Sci Res. 2020; 8(4): 293–300.
- Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M, et al. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? PLoS One. 2018; 13(3): e0194270.
- Potenza E, Parpinel G, Laudani ME, et al. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer. Int J Biol Markers. 2020; 35(4): 20–27.
- Vallius T, Hynninen J, Auranen A, et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol. 2014; 35(12): 12389–12395.
- Capriglione S, Luvero D, Plotti F, et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol. 2017; 34(9): 164.
- Shen Y, Li Li. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumor Biology. 2016; 37(11): 14765–14772.
- Plotti F, Scaletta G, Capriglione S, et al. The role of HE4, a novel biomarker, in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer. 2017; 27(4): 696–702.
